FR12C0041I2 - Analogues de somatostatine - Google Patents

Analogues de somatostatine

Info

Publication number
FR12C0041I2
FR12C0041I2 FR12C0041C FR12C0041C FR12C0041I2 FR 12C0041 I2 FR12C0041 I2 FR 12C0041I2 FR 12C0041 C FR12C0041 C FR 12C0041C FR 12C0041 C FR12C0041 C FR 12C0041C FR 12C0041 I2 FR12C0041 I2 FR 12C0041I2
Authority
FR
France
Prior art keywords
somatostatin analogs
somatostatin
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR12C0041C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9896782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR12C0041I1 publication Critical patent/FR12C0041I1/fr
Application granted granted Critical
Publication of FR12C0041I2 publication Critical patent/FR12C0041I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
FR12C0041C 2000-08-01 2012-06-26 Analogues de somatostatine Active FR12C0041I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018891.2A GB0018891D0 (en) 2000-08-01 2000-08-01 Organic compounds
PCT/EP2001/008824 WO2002010192A2 (fr) 2000-08-01 2001-07-30 Analogues de somatostatine

Publications (2)

Publication Number Publication Date
FR12C0041I1 FR12C0041I1 (fr) 2012-07-27
FR12C0041I2 true FR12C0041I2 (fr) 2013-01-11

Family

ID=9896782

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0041C Active FR12C0041I2 (fr) 2000-08-01 2012-06-26 Analogues de somatostatine

Country Status (35)

Country Link
US (5) US7473761B2 (fr)
EP (1) EP1307486B1 (fr)
JP (1) JP3829118B2 (fr)
KR (2) KR100799394B1 (fr)
CN (1) CN1267451C (fr)
AR (1) AR034132A1 (fr)
AT (1) ATE393782T1 (fr)
AU (2) AU8977801A (fr)
BE (1) BE2012C026I2 (fr)
BR (1) BRPI0112859B8 (fr)
CA (1) CA2416293C (fr)
CY (2) CY1108547T1 (fr)
CZ (1) CZ302461B6 (fr)
DE (1) DE60133823T2 (fr)
DK (1) DK1307486T3 (fr)
EC (1) ECSP034456A (fr)
ES (1) ES2305104T3 (fr)
FR (1) FR12C0041I2 (fr)
GB (1) GB0018891D0 (fr)
HU (1) HU227812B1 (fr)
IL (2) IL153920A0 (fr)
LU (1) LU92024I2 (fr)
MX (1) MXPA03000991A (fr)
MY (1) MY138074A (fr)
NO (2) NO331093B1 (fr)
NZ (1) NZ523836A (fr)
PE (1) PE20020176A1 (fr)
PL (1) PL204161B1 (fr)
PT (1) PT1307486E (fr)
RU (1) RU2287533C2 (fr)
SI (1) SI1307486T1 (fr)
SK (1) SK287798B6 (fr)
TW (1) TWI282341B (fr)
WO (1) WO2002010192A2 (fr)
ZA (1) ZA200300406B (fr)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
WO2003057214A1 (fr) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Derives d'hydantoine presentant une affinite pour les recepteurs de la somatostatine
US7294722B2 (en) * 2002-12-12 2007-11-13 Novartis Ag Process for the synthesis of peptides containing a 4-hydroxy-proline substructure
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
GB0314695D0 (en) * 2003-06-24 2003-07-30 Novartis Ag Organic compounds
GB0318682D0 (en) * 2003-08-08 2003-09-10 Novartis Ag Organic compounds
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
US20090197815A1 (en) * 2006-06-08 2009-08-06 Beatrice Vincenzi Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist
US7697338B2 (en) * 2006-11-16 2010-04-13 Sandisk Corporation Systems for controlled boosting in non-volatile memory soft programming
CN101553728B (zh) * 2006-11-28 2013-02-06 香港大学 颗粒体蛋白-上皮素前体(gep)抗体用于检测和抑制肝细胞癌(hcc)的用途
EP1941902A1 (fr) * 2007-01-02 2008-07-09 Novartis AG Utilisation d' analogues de somatostatin pour le traitment de chéphalée vasculaire de horton
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (fr) 2007-03-28 2016-10-19 President and Fellows of Harvard College Polypeptides piqués
PE20090387A1 (es) 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
WO2009009035A1 (fr) * 2007-07-06 2009-01-15 Ipsen Pharma S.A.S. Analogue de la somatostatine et ses utilisations
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
US20100273719A1 (en) 2007-11-28 2010-10-28 Novartis Ag Use of somatostatin analogs in meningioma
CN101883785B (zh) 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物
EP2067786A1 (fr) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Nouveaux analogues non sélectifs de somatostatine
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
US9314508B2 (en) 2008-07-08 2016-04-19 Novartis Ag Use of somatostatin analogs in control of hypoglycemia
EP2172189A1 (fr) 2008-10-01 2010-04-07 Novartis AG Compositions pharmaceutiques
EP2213307A1 (fr) 2009-02-03 2010-08-04 Novartis AG Formulations de dépôt injectables
RU2678833C2 (ru) 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2012074559A2 (fr) 2010-12-02 2012-06-07 New York University Traitement d'une maladie kystique non proliférative
JP2014501235A (ja) 2010-12-13 2014-01-20 ノバルティス アーゲー 二量体ｉａｐ阻害剤
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20130035054A1 (en) * 2011-07-14 2013-02-07 Faceon Mobile Phone with multi-portal access for display during incoming and outgoing call
WO2013019923A2 (fr) 2011-08-02 2013-02-07 New York University Procédés de détection de cellules progénitrices et utilisations de celles-ci
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9555118B2 (en) 2011-12-05 2017-01-31 Camrus Ab Robust controlled-release peptide formulations
US20140329858A1 (en) 2011-12-05 2014-11-06 Novartis Ag Cyclic Urea Derivatives As Androgen Receptor Antagonists
BR112014016870A2 (pt) 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
PE20150195A1 (es) * 2012-05-25 2015-02-27 Camarus Ab Formulaciones de agonistas del receptor de somatostatina
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
WO2014071241A1 (fr) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Acides aminés disubstitués et procédés de préparation et d'utilisation de ceux-ci
EP2922578B1 (fr) 2012-11-21 2018-12-12 Serene, Llc Composés de liaison de récepteur somatostatine comprenant l'isotope de l'etain 117m
NZ710385A (en) 2013-02-19 2016-10-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
MX2015012822A (es) 2013-03-14 2016-05-31 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
CA2903979A1 (fr) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
WO2014147586A1 (fr) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(éthylamino)pyrimidin-4-yl)pyrrolidin-2-ones en tant qu'inhibiteurs du mutant idh
CN103467575B (zh) * 2013-08-22 2016-03-02 深圳翰宇药业股份有限公司 一种帕西瑞肽的制备方法
CN103641894B (zh) * 2013-12-06 2015-10-28 深圳翰宇药业股份有限公司 一种治疗库欣病的多肽药物的制备方法
WO2015092634A1 (fr) 2013-12-16 2015-06-25 Novartis Ag Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes
US20180133147A1 (en) 2013-12-19 2018-05-17 Novartis Ag Drug Delivery Systems
WO2015107494A1 (fr) 2014-01-17 2015-07-23 Novartis Ag Dérivés de 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine et compositions les contenant pour l'inhibition de l'activité de shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
AU2015265607A1 (en) 2014-05-28 2016-11-17 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10086000B2 (en) 2014-12-05 2018-10-02 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
US10442819B2 (en) 2014-12-05 2019-10-15 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
WO2016089830A1 (fr) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Nouveaux composés tricycliques utilisés en tant qu'inhibiteurs d'enzymes idh mutantes
EP3229824A4 (fr) 2014-12-10 2018-07-11 Chiasma Inc. Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques
EP3233899B1 (fr) 2014-12-19 2020-06-24 Auro Peptides LTD Procédé de préparation de pasiréotide
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
WO2016154058A1 (fr) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
WO2016162127A1 (fr) * 2015-04-08 2016-10-13 Polyphor Ag Peptidomimétiques à squelette cyclisé
EP3303361A1 (fr) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucléotides pour le traitement du cancer
EP3310779B1 (fr) 2015-06-19 2019-05-08 Novartis AG Composés et compositions pour l'inhibition de l'activité de shp2
WO2016203406A1 (fr) 2015-06-19 2016-12-22 Novartis Ag Composés et compositions pour inhiber l'activité de shp2
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
WO2016207912A1 (fr) * 2015-06-22 2016-12-29 Biophore India Pharmaceuticals Pvt. Ltd. Nouveau procédé de préparation de pasiréotide
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
EP3328418A1 (fr) 2015-07-29 2018-06-06 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
EP3389783B1 (fr) 2015-12-15 2024-07-03 Merck Sharp & Dohme LLC Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
DK3452465T3 (da) 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
EP3507367A4 (fr) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
JP6636673B2 (ja) 2016-10-04 2020-01-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＳＴＩＮＧアゴニストとしてのベンゾ［ｂ］チオフェン化合物
US20190365788A1 (en) 2016-11-21 2019-12-05 Idenix Pharmaceuticals Llc Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
ES2891326T3 (es) 2017-01-27 2022-01-27 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de la STING
ES2924186T3 (es) 2017-01-27 2022-10-05 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de STING
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
JP7447002B2 (ja) 2017-09-11 2024-03-11 クルーゾン・ファーマシューティカルズ・インコーポレイテッド ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
WO2019067332A1 (fr) 2017-09-27 2019-04-04 Merck Sharp & Dohme Corp. Compositions et procédés de traitement du cancer par une combinaison d'anticorps anti-récepteur de mort programmée (pd-1) et d'un antagoniste de cxcr2
WO2019078968A2 (fr) * 2017-10-18 2019-04-25 Angex Pharmaceutical, Inc. Composés cycliques en tant qu'agents immunomodulateurs
US12275729B2 (en) 2017-11-01 2025-04-15 Merck Sharp & Dohme Llc Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2019099294A1 (fr) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Nouveaux composés biaryles substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
AU2018368332B2 (en) 2017-11-14 2022-05-12 Merck Sharp & Dohme Llc Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
MX2020006290A (es) 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.
WO2019125974A1 (fr) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Composés dinucléotidiques cycliques utilisés comme agonistes sting
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
US11542505B1 (en) 2018-04-20 2023-01-03 Merck Sharp & Dohme Llc Substituted RIG-I agonists: compositions and methods thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019231870A1 (fr) 2018-05-31 2019-12-05 Merck Sharp & Dohme Corp. Nouveaux composés [1,1,1]bicyclo substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase
WO2019231871A1 (fr) 2018-06-01 2019-12-05 Merck Sharp & Dohme Corp. Nouveaux composés [3.3.1]bicyclo en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase
EP3810615B1 (fr) 2018-06-20 2026-01-28 Merck Sharp & Dohme LLC Inhibiteurs d'arginase et procédés d'utilisation
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US20200030466A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
JP7337174B2 (ja) 2018-09-18 2023-09-01 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
EP3856349A1 (fr) 2018-09-25 2021-08-04 Black Diamond Therapeutics, Inc. Compositions d'inhibiteur de tyrosine kinase, procédés de fabrication et procédés d'utilisation
WO2020068867A1 (fr) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Dérivés de quinazoline utilisés en tant qu'inhibiteur de tyrosine kinase, compositions, leurs procédés de préparation et leur utilisation
EP3856345A1 (fr) 2018-09-29 2021-08-04 Novartis AG Procédé de fabrication d'un composé pour inhiber l'activité de shp2
US12091405B2 (en) 2018-11-01 2024-09-17 Merck Sharp & Dohme Llc Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
WO2020096871A1 (fr) 2018-11-06 2020-05-14 Merck Sharp & Dohme Corp. Nouveaux composés tricycliques substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase
EP3886845B1 (fr) 2018-11-28 2024-09-04 Merck Sharp & Dohme LLC Nouveaux composés de piperazine amide substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
EP3897622B1 (fr) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Inhibiteurs d'arginase et procédés d'utilisation
US12281109B2 (en) 2019-04-04 2025-04-22 Merck Sharp & Dohme Llc Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
WO2020260547A1 (fr) 2019-06-27 2020-12-30 Rigontec Gmbh Procédé de conception pour ligands rig-i optimisés
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
EP4053124A1 (fr) 2019-10-28 2022-09-07 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Composé d'acide oxocarboxylique hétérocyclique à cinq chaînons et son utilisation médicale
US20230074558A1 (en) 2019-12-06 2023-03-09 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
EP4076443B1 (fr) 2019-12-17 2025-09-10 Merck Sharp & Dohme LLC Composé de 1,3,8-triazaspiro[4,5] décane-2,4-dione substitué en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) et/ou du tryptophane 2,3-dioxygénase (tdo)
US20230140132A1 (en) 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021195206A1 (fr) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Formes polymorphes et utilisations associées
CN116196435B (zh) 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
CR20220565A (es) 2020-05-06 2023-01-13 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos de uso
AU2021409561A1 (en) 2020-12-22 2023-07-06 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
WO2022170052A1 (fr) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Dérivés de quinazoline, dérivés de pyridopyrimidine, dérivés de pyrimidopyrimidine et leurs utilisations
EP4323350A1 (fr) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Composés d'iso-indolinone
WO2022219412A1 (fr) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Composés amide d'isoindolinone utilisés pour traiter des maladies associées à gspt1
WO2022227015A1 (fr) 2021-04-30 2022-11-03 Merck Sharp & Dohme Corp. Inhibiteurs d'il4i1 et méthodes d'utilisation
WO2023284730A1 (fr) 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Dérivés d'alkylidène en tant qu'inhibiteurs de kras
KR20240167846A (ko) 2022-03-28 2024-11-28 니캉 테라퓨틱스 인코포레이티드 사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체
CN119790053A (zh) 2022-06-08 2025-04-08 霖康疗法公司 作为细胞周期蛋白依赖性激酶2抑制剂的磺酰胺衍生物
JP2025528439A (ja) * 2022-08-30 2025-08-28 グラフトン セラピューティクス エスアエールエル 複数のソマトスタチン受容体サブタイプ選択性を有するハロゲン化ソマトスタチン類似体
IL320316A (en) 2022-11-11 2025-06-01 Nikang Therapeutics Inc Bifunctional compounds containing pyrimidine derivatives with substitutions at positions 2 and 5, for degradation of cyclin-dependent kinase 2 (CDK2) via the ubiquitin-proteasome pathway
AR132248A1 (es) 2023-03-29 2025-06-11 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos para su uso
KR20260042361A (ko) 2023-06-30 2026-03-31 머크 샤프 앤드 돔 엘엘씨 치료 조합물, 및 이의 용도 및 치료 방법
WO2025072462A1 (fr) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Dérivés sulfonamides utilisés en tant qu'inhibiteurs de la kinase 2 dépendante de la cycline
CN122249438A (zh) 2023-11-27 2026-06-19 霖康疗法公司 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2和细胞周期蛋白依赖性激酶4的含有2,5-取代的嘧啶衍生物的双功能化合物
CN122341597A (zh) 2023-12-02 2026-07-03 霖康疗法公司 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有2,5-取代的嘧啶衍生物的双功能化合物
WO2025212828A1 (fr) 2024-04-03 2025-10-09 Nikang Therapeutics, Inc. Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase cycline-dépendante 2 et la kinase cycline-dépendante 4 par l'intermédiaire de la voie ubiquitine-protéasome
WO2025240536A1 (fr) 2024-05-15 2025-11-20 Nikang Therapeutics, Inc. Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante d'une cycline et/ou la kinase 4 dépendante d'une cycline par l'intermédiaire de la voie ubiquitine-protéasome

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) * 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) * 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4612386A (en) * 1980-09-16 1986-09-16 The Dow Chemical Company Process for making esters
US4505897A (en) * 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) * 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (fr) 1989-03-15 2001-07-03 Biomeasure, Inc. Somatostatines iodees
CA2053250A1 (fr) 1989-04-26 1990-10-27 David H. Coy Analogues lineaires de la somatostatine
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
DE69426673T2 (de) 1993-06-23 2001-09-20 Diatide, Inc. Radiomarkierte somatostatin derivate zur abbildung und zur therapeutischen verwendung
EP1288224B1 (fr) 1993-08-09 2008-06-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Derivées des peptides therapeutiques
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9513224D0 (en) * 1995-06-29 1995-09-06 Sandoz Ltd Organic compounds
IT1277391B1 (it) 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
AU2764797A (en) 1996-05-14 1997-12-05 Novo Nordisk A/S Somatostatin agonists and antagonists
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
CA2246791A1 (fr) 1998-09-01 2000-03-01 Alison Buchan Traitement de l'endothelium avec des analogues de la somatostatine
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HK1057051A1 (en) 2004-03-12
US20050014686A1 (en) 2005-01-20
CA2416293A1 (fr) 2002-02-07
BRPI0112859B1 (pt) 2016-03-01
US7939625B2 (en) 2011-05-10
BR0112859A (pt) 2003-07-01
US20110166320A1 (en) 2011-07-07
AR034132A1 (es) 2004-02-04
US9035021B2 (en) 2015-05-19
ATE393782T1 (de) 2008-05-15
SK1212003A3 (en) 2003-08-05
ZA200300406B (en) 2004-04-02
FR12C0041I1 (fr) 2012-07-27
RU2287533C2 (ru) 2006-11-20
SI1307486T1 (sl) 2008-08-31
NO20030484D0 (no) 2003-01-30
PL358718A1 (en) 2004-08-09
WO2002010192A3 (fr) 2002-09-19
CZ302461B6 (cs) 2011-06-01
MXPA03000991A (es) 2003-06-09
PL204161B1 (pl) 2009-12-31
ECSP034456A (es) 2003-03-10
US20150218223A1 (en) 2015-08-06
US7473761B2 (en) 2009-01-06
NO20030484L (no) 2003-03-19
CN1446229A (zh) 2003-10-01
ES2305104T3 (es) 2008-11-01
CN1267451C (zh) 2006-08-02
PT1307486E (pt) 2008-07-31
CY1108547T1 (el) 2014-04-09
IL153920A (en) 2010-12-30
EP1307486B1 (fr) 2008-04-30
NO2012012I1 (no) 2012-06-29
IL153920A0 (en) 2003-07-31
EP1307486A2 (fr) 2003-05-07
CY2012018I1 (el) 2015-10-07
US8822637B2 (en) 2014-09-02
MY138074A (en) 2009-04-30
JP2004505095A (ja) 2004-02-19
NZ523836A (en) 2004-08-27
WO2002010192A2 (fr) 2002-02-07
KR20060035809A (ko) 2006-04-26
HU227812B1 (hu) 2012-03-28
US20090069225A1 (en) 2009-03-12
PE20020176A1 (es) 2002-03-26
DE60133823T2 (de) 2009-05-20
DK1307486T3 (da) 2008-08-25
GB0018891D0 (en) 2000-09-20
HUP0300684A2 (hu) 2003-09-29
CZ2003288A3 (cs) 2003-05-14
CY2012018I2 (el) 2015-10-07
CA2416293C (fr) 2011-05-10
SK287798B6 (sk) 2011-10-04
HUP0300684A3 (en) 2004-08-30
AU2001289778B2 (en) 2005-02-03
US20110172157A1 (en) 2011-07-14
BRPI0112859B8 (pt) 2021-05-25
NO331093B1 (no) 2011-10-03
AU8977801A (en) 2002-02-13
BE2012C026I2 (fr) 2020-12-15
LU92024I2 (fr) 2012-08-20
NO2012012I2 (no) 2012-07-30
DE60133823D1 (de) 2008-06-12
KR20030033008A (ko) 2003-04-26
JP3829118B2 (ja) 2006-10-04
TWI282341B (en) 2007-06-11
WO2002010192A9 (fr) 2002-10-17
KR100799394B1 (ko) 2008-01-30

Similar Documents

Publication Publication Date Title
EP1353683A4 (fr) Analogues de la ghreline
DK1307486T3 (da) Somatostatinanaloger
DZ3388A1 (fr) Analogues de peptide 1 du type glucagon
DK1124779T3 (da) D-vitaminanaloge forbindelser
DE69941708D1 (de) Pacap-peptidanaloga
EE03832B1 (et) Heptapeptiidanaloogid
DK1235777T3 (da) Vitamin D-analoger
DK1401863T3 (da) Kimære somatostatin-dopamin-analoge
AU2002360487A8 (en) Acyclovir-peptide analogs
EP1594529A4 (fr) Analogues de glp-1
EP1651662A4 (fr) Analogues antagonistes de gh-rh (2003)
EP1397150A4 (fr) Agonistes de la somatostatine
NO20020161D0 (no) Vitamin D3-analoger
DK1235824T3 (da) D-vitaminanaloge forbindelser
NO20006320D0 (no) Cykliske somatostatin-analoger
EP1549309A4 (fr) Composes analogues de la somatostatine
DK1372688T3 (da) Somatostatin-antagonister
NO20041066L (no) Hydroksyeikosensyre-analoger
EP1255770A4 (fr) Analogues de l'hormone concentratrice de la melanine
NO20032913D0 (no) Neurotrofiske tacrolimusanaloger
EP1211241A4 (fr) Analogues de la prostaglandine e
DK1137667T3 (da) GLP-1-analoger
DK1143992T3 (da) Terapeutisk sammensætninger indeholdende glutathionanaloge
SE0003187D0 (sv) Novel enkephalin analogues